Certara Investor Day Presentation Deck

Virtual drug development for a neglected, tropical disease Certara formed a virtual drug development team with Medicines Development for Global Health to work on moxidectin, a treatment for onchocerciasis or river blindness. River blindness is the second leading cause of infectious blindness, affecting at least 25 million people worldwide. ● ● Drug development and regulatory strategy Clinical pharmacology ● ● Population PK/PD analysis and NCA Clinical trial design ● ● Phoenix Software Epidemiology modeling FDA Approval Approved by the FDA as the first medication in 20 years to treat patients 12 and older Client received a tropical disease priority review voucher 72 CERTARA

View entire presentation